Head to Head Survey: Interpace Diagnostics Group (IDXG) and Lombard Medical (EVARF)

Share on StockTwits

Lombard Medical (OTCMKTS:EVARF) and Interpace Diagnostics Group (NASDAQ:IDXG) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Valuation & Earnings

This table compares Lombard Medical and Interpace Diagnostics Group’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lombard Medical $12.17 million 0.02 -$31.03 million N/A N/A
Interpace Diagnostics Group $15.90 million 2.45 -$12.21 million ($0.81) -1.68

Interpace Diagnostics Group has higher revenue and earnings than Lombard Medical.

Analyst Recommendations

This is a breakdown of current recommendations for Lombard Medical and Interpace Diagnostics Group, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lombard Medical 0 0 0 0 N/A
Interpace Diagnostics Group 0 0 4 0 3.00

Interpace Diagnostics Group has a consensus price target of $3.44, suggesting a potential upside of 152.76%. Given Interpace Diagnostics Group’s higher probable upside, analysts plainly believe Interpace Diagnostics Group is more favorable than Lombard Medical.

Risk and Volatility

Lombard Medical has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, Interpace Diagnostics Group has a beta of 2.35, indicating that its share price is 135% more volatile than the S&P 500.

Insider & Institutional Ownership

12.5% of Interpace Diagnostics Group shares are owned by institutional investors. 2.8% of Interpace Diagnostics Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


This table compares Lombard Medical and Interpace Diagnostics Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lombard Medical N/A N/A N/A
Interpace Diagnostics Group -71.14% -34.58% -25.64%


Interpace Diagnostics Group beats Lombard Medical on 8 of the 11 factors compared between the two stocks.

Lombard Medical Company Profile

Lombard Medical, Inc., a medical technology company, develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, Japan, and internationally. The company's principal product is Aorfix, which is an endovascular stent-graft for the treatment of abdominal aortic aneurysms (AAAs) with angulation at the neck of the aneurysm of up to 90 degrees. Its products also include Altura endovascular stent graft system for the treatment of standard AAA anatomies; Aorflex delivery system for accurate placement of Aorfix in the abdominal aorta; and IntelliFlex LP delivery system that enhances the precision and control of Aorfix deployment and placement. Lombard Medical, Inc. sells its products directly through its direct sales force and distributors to state-or-government-owned hospitals. The company was founded in 2000 and is headquartered in Didcot, the United Kingdom.

Interpace Diagnostics Group Company Profile

Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules. The company's customers consist primarily of physicians, hospitals, and clinics. The company was formerly known as PDI, Inc. and changed its name to Interpace Diagnostics Group, Inc. in December 2015. Interpace Diagnostics Group, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Receive News & Ratings for Lombard Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lombard Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply